Hormone swings can shake your mood, and the risk gathers around the change itself: perimenopause, the weeks after birth, surgical menopause, and any time hormone therapy is interrupted. Who is vulnerable, and how to catch it early.

Hormone swings can shake your mood, and the risk gathers around the change itself: perimenopause, the weeks after birth, surgical menopause, and any time hormone therapy gets interrupted. It doesn't hit everyone. It hits enough people that we should be talking about it.

A note on language. Menopause comes from ovarian hormones, not gender. Pregnancy, PMDD and hormone therapy happen to people of every gender. Most studies cited here enrolled cisgender women and said so, so I write "women" only when that's who was studied. Everywhere else it's "people." Where the research skips trans, non-binary and intersex people, I say that too.

The brain runs on hormones, so hormone change is brain change

Estrogen receptors sit throughout the brain's mood circuits. When estrogen swings, serotonin, dopamine and GABA signalling swing with it. The Massachusetts General Hospital (MGH) Center for Women's Mental Health describes estrogen as protective for the brain and mood, and notes that in perimenopause levels fluctuate widely before they fall.

The idea that ties this piece together: withdrawal and volatility matter, alongside low levels. A 2015 review describes perimenopause as a neurological transition, where falling estrogen in estrogen-dependent brain regions drives changes in sleep, mood and thinking (Brinton et al., 2015). The same pattern shows up after birth, after surgery, and when hormone therapy stops.

Two reality checks. Hormones aren't the only thing going on. SWAN found stressful life events, poor sleep, hot flashes and childhood adversity often predicted depressive symptoms more strongly than hormone levels did, and studies tying specific hormone levels to mood have been inconsistent. And most people move through these transitions without a mental health crisis. The useful question is who's vulnerable, and how to catch it early.

Perimenopause is the highest-risk window, and the risk is real but not universal

Pooling seven cohort studies of 9,141 women, perimenopause carried about 40% higher odds of depressive symptoms or a depression diagnosis than premenopause. Postmenopause showed no significant increase (Badawy et al., 2024).

Finding	The numbers	Source
Perimenopause vs premenopause	40% higher odds of depression (the true number probably sits between 1.21 and 1.61 times higher), 7 cohorts, 9,141 women	Badawy et al., J Affect Disord 2024
Postmenopause vs premenopause	No clear increase (18% higher odds, but the range 0.74 to 1.86 includes no effect, so it could be nothing)	Badawy et al., 2024
History matters most	59% with prior major depression vs 28% without	SWAN, via MGH
Age at menopause	Menopause at 40 or later: about half the depression risk of premature menopause (14 studies, 67,714 women)	Georgakis et al., JAMA Psychiatry 2016

Two things stand out. A history of depression is the strongest predictor, but it isn't the only one: in the Harvard Study of Moods and Cycles, women with no depression history who entered perimenopause were about twice as likely to develop significant depressive symptoms as those who stayed premenopausal (Cohen et al., Arch Gen Psychiatry 2006). And the "hot flashes disrupt sleep, poor sleep lowers mood" chain explains only part of it: in three studies in the 2024 review, the risk held after adjusting for vasomotor symptoms (Badawy et al., 2024).

There's a screening gap too. Doctors and specialists are prompted to screen pregnant and postpartum people for depression, while people in perimenopause, who are similarly vulnerable, rarely get the same prompt (MGH).

Surgical and chemical menopause: a sudden stop

When both ovaries are removed, or cancer or endometriosis treatment shuts them down, menopause arrives overnight. That includes oophorectomy as part of gender-affirming surgery, which can bring this sudden stop decades earlier than natural menopause. The evidence on mood is mixed, and the mix is worth showing.

Higher long-term risk in one large cohort. In Olmsted County, Minnesota, women who had both ovaries removed before menopause for a non-cancer reason were 1.54 times more likely to have later depressive symptoms and 2.29 times more likely to have anxiety symptoms, compared with age-matched women who kept theirs. The association held after excluding symptoms in the first 10 years (Rocca et al., Menopause 2018).
No worse than natural menopause in another. In SWAN, 1,970 women followed for up to 10 years, hysterectomy with oophorectomy wasn't linked to more depression or anxiety than natural menopause. The surgical group was small: 101 women (via MGH).
A first-year rise that mostly settles, though not for everyone. In the WHAM ("What happens after menopause?") study, 59 BRCA carriers having risk-reducing salpingo-oophorectomy were compared with 91 people who kept their ovaries. Depressive symptoms were raised at 6 and 12 months, and anxiety at 6 months. By 24 months, symptoms weren't elevated overall. People with raised symptoms at 12 months were far more likely to still have them at 24 months, and hormone therapy use showed no link to symptoms either way (Hickey et al., Gynecol Oncol 2024).

A fair summary: some people are hit hard, timing matters, and "it might pass" isn't a reason to wait. I went into chemical menopause almost overnight during cancer treatment, and Nila has a treatment-induced menopause pathway for exactly this. One practical point from Nila's mood page, drawn from a small 2026 study of 9 carers and 19 staff at a UK private menopause clinic (Hendriks et al., Health Expectations 2026; funded by the clinic group, Newson Health, so treat it as industry-funded): suicidal thoughts around menopause can fall between hormone care and mental health care, with each side assuming the other has it covered. Name both in the same appointment, and ask who's coordinating.

Postpartum: one of the sharpest hormone drops the body goes through

Within days of delivery, estradiol and progesterone fall from pregnancy's very high levels to near-menopausal levels. Postpartum depression is commonly estimated to affect 10% to 15% of people who give birth, though estimates vary by country and method, and most studies enrolled mothers.

The strongest direct evidence in this piece comes from a small NIMH experiment (Bloch, Schmidt et al., Am J Psychiatry 2000). Researchers switched off ovarian hormones in 16 women with a drug, added back pregnancy-level estradiol and progesterone for eight weeks, then withdrew both, double-blind. Five of the eight women with a history of postpartum depression (62.5%) developed significant mood symptoms during withdrawal. None of the eight comparison women did. The authors concluded these hormones play a role in postpartum depression for a subgroup who are more sensitive to hormone change. That changes the question. The better question is whose brain reacts most strongly to the swing.

One proposed pathway runs through allopregnanolone, a progesterone breakdown product that calms the brain through GABA-A receptors, rises sharply in pregnancy and falls after birth. It's the basis for brexanolone and zuranolone, the first medicines approved specifically for postpartum depression.

Withdrawal isn't the whole story, though. In a UK cohort of about 9,000 women (the Avon Longitudinal Study of Parents and Children), 13.5% scored above the threshold for probable depression at 32 weeks of pregnancy, compared with 9.1% at 8 weeks postpartum (Evans et al., BMJ 2001). Screening and support belong in pregnancy too, not just after birth.

Support: Postpartum Support International is a good place to start.

Hormone-sensitive brains: PMDD, ADHD and autism

Some brains respond more strongly to the same hormone swings.

PMDD. Premenstrual dysphoric disorder affects about 3% to 8% of people who menstruate during their reproductive years (studies usually counted women), and many go unrecognized (MGH). A meta-analysis of six studies and 8,532 people linked PMDD to about 2.3 times higher odds of suicidal thoughts, 2.2 times higher odds of plans, and 2.1 times higher odds of attempts. The limit: PMDD was identified by screening questionnaires, not the daily symptom diaries a diagnosis requires, and the studies can't show cause (Yan et al., J Affect Disord 2021). In a Swedish study of 110 women with PMDD confirmed by daily ratings, 39.1% reported current suicidal thoughts in the late luteal phase (Wikman et al., BMC Women's Health 2022). Researchers from the International Association for Premenstrual Disorders have argued suicidality should be considered for the PMDD diagnostic criteria (Gordon et al., Lancet Psychiatry 2024). PMDD often intensifies in perimenopause before it ends, which puts it squarely in this picture.

ADHD and autism. Estrogen modulates dopamine, so when it swings, executive function, emotional regulation and sensory tolerance can all get harder. That's neurochemistry (Kooij, de Jong et al., Front Glob Womens Health 2025). A 2026 study of 602 women found those with ADHD reported more irregular cycles, worse premenstrual symptoms, more postpartum depression and more severe menopausal symptoms than women without ADHD (Boyd, Wrigley et al., Archives of Women's Mental Health 2026; ADHD was self-reported and the study was a one-time survey).

The autistic-menopause evidence has moved on from the first small studies. In “A perfect storm”, 24 autistic people in Canada and the UK described intense, overlapping symptoms, midlife pressures converging, the importance of knowledge and connection, and barriers to support (Brady et al., Autism 2024). In “Struggling for Years”, an international, co-produced survey of 508 autistic participants linked poorer autism and menopause awareness with greater difficulty; participants wanted autistic-specific information and better-informed care (Jenkins et al., Neurodiversity 2024). A 2026 community-led research agenda now sets out seven priorities and calls for research that includes gender-diverse and other marginalized autistic people (Jenkins & Janse van Rensburg, Women's Health 2026).

This is a stronger evidence base than we had in 2020, but it still doesn't tell us what every autistic person will experience. The 24-person study may over-represent difficult experiences, and the larger survey shows associations rather than cause. I'd rather say that plainly than overstate it.

Trans, non-binary and gender-diverse people: hormones can help, and the midlife evidence is thin

For many trans people, starting hormones is itself a mental health intervention. When your hormones are also how you become yourself, every swing, every gap in access, every forced stop carries double weight: body and identity at once. A 2023 Nature Human Behaviour review of 46 studies found gender-affirming hormone therapy was consistently linked to fewer depressive symptoms and less psychological distress. Quality-of-life results were mixed, and the authors flagged small samples and weak adjustment for factors like surgery and stigma, so cause is hard to pin down (Doyle, Lewis & Barreto, 2023). A 2021 Journal of the Endocrine Society review of 20 studies pointed the same way, with low-strength evidence (Baker et al., 2021).

The 2023 review also notes that about one in three trans people report a suicide attempt in their lifetime, and links that risk partly to stigma and social disruption. Both things are true: stigma is a documented driver of distress, and hormone therapy is consistently linked to less of it.

What's known and unknown in midlife. There are two different physiological stories. For trans women, estrogen can drop through dose changes, lost access to prescriptions, orchiectomy, or ageing on long-term therapy. For trans men and non-binary people assigned female at birth, the ovaries keep ageing on their own clock whether or not testosterone stops periods, and surgical menopause can come young when oophorectomy is part of gender-affirming surgery.

On mood specifically, research on hormones in trans people has focused on starting and staying on therapy, not on midlife. The 2023 review adds that nobody yet knows whether the psychological gains reverse if therapy stops. A 2025 review in Current Opinion in Obstetrics & Gynecology puts it plainly: research on menopause in transgender and gender-diverse people is lacking, and there are no guidelines for clinical management yet (Kelley & Ariel, 2025). That gap deserves naming, and more research.

Who the research leaves out, and where to look instead

Most menopause and mood research was built on cisgender women, and mostly white, middle-class ones. There's real work on other communities, though.

Community	What the research says	Where to start
LGBTQ+ people	A 2025 review found LGBTQ+ people have poorer physical and mental health, largely through minority stress, and more dissatisfaction with healthcare, and set out a research agenda (Westwood, Health 2025, online 2024).	Queer Menopause; Pink Therapy
Black people	A review of 25 years of SWAN research found Black women reach menopause about 8.5 months earlier than white women, with more severe symptoms including depression and sleep problems, and are less likely to receive hormone therapy. The authors point to structural racism as a major driver (Harlow et al., Women's Midlife Health 2022).	Nila's Black people and midlife doorway; Black Women's Health Imperative (Power in the Pause)
Latina and other racialized people	SWAN found depressive symptoms rise across the transition, with Hispanic and African American women appearing most vulnerable (Green & Santoro, 2009).	Nila's people of colour and midlife page; Inclusive Therapists
Indigenous people	I couldn't find menopause-and-mood research specific to Indigenous people. That gap is worth saying out loud.	Hope for Wellness, 1-855-242-3310, Indigenous-led, 24/7 (Canada)

Two caveats. SWAN is a landmark study, but it enrolled only women and didn't measure racism directly, so the racism link is inferred. And Nila's editorial voice is white-led; we're commissioning paid Black writers and reviewers, so lean on the research and community organizations above as much as on us.

What helps: a stack, not a single fix

Pair a medical option with a daily-life change, and give it time. Nila's mood page suggests at least one of each and about six weeks before judging. This is education, not medical advice. Decisions belong with a doctor or specialist who knows your history.

Hormone therapy can help mood in perimenopause, modestly. A 2026 meta-analysis of 12 randomized trials (835 women) found a small reduction in depressive symptoms versus placebo (a standardized effect size of 0.23, which is considered small), with limited certainty (Li et al., J Affect Disord 2026). An earlier trial of 50 perimenopausal women with depressive disorders reported remission in 68% on transdermal estradiol versus 20% on placebo (Soares et al., Arch Gen Psychiatry 2001). A randomized trial of 172 women found transdermal estradiol plus intermittent micronized progesterone reduced the chance of developing clinically significant depressive symptoms in women who started out symptom-free (Gordon et al., JAMA Psychiatry 2018).
For diagnosed depression, standard care still comes first. Reviews generally place antidepressants and psychotherapy as first-line, with estrogen's evidence more debated, though its possible antidepressant effect is noted especially in people who also have hot flashes and night sweats (network meta-analysis, Psychiatry Research 2023).
Therapy works, and fit matters. MGH highlights CBT and mindfulness-based approaches for anxiety and depression in perimenopause. Ask any therapist whether they know perimenopause and menopause, what a typical course looks like, and how you'll both know it's working.
Daily levers. Nila's mood page lists a 30-minute daily walk, strength training twice a week, and saffron plus EPA-rich omega-3 as evidence-tagged, and a "dry month" as a personal-experience pick. Those are Nila's evidence grades; check them in the research library.
Stopping hormones can bring symptoms back. In a randomized trial, women with a history of perimenopausal depression whose symptoms had improved on estradiol developed depressive symptoms again when it was swapped for placebo. Comparison women didn't (Schmidt et al., JAMA Psychiatry 2015). Talk with your prescriber before changing a dose.

Also worth knowing: heart symptoms in midlife women are often mistaken for anxiety, and low mood with brain fog and exhaustion can also come from thyroid problems, low iron or sleep apnea. It's reasonable to ask about TSH, free T4, ferritin, vitamin D and a proper sleep history before settling on "it's probably menopause."

Resources

On Nila

Mood and anxiety in midlife
Finding support
Trans and non-binary midlife
Neurodivergent and midlife
Treatment-induced menopause
While you wait for your appointment (includes the three-minute Menopause Rating Scale)
Who Nila is for
Research library

Find a therapist or community

Directory	Best for
BRIA Academy Menopause Mental Health Provider Directory	Canadian providers with menopause mental health training. It's a training credential, not a licence, so confirm registration with the provincial college.
BC Association of Clinical Counsellors	Registered Clinical Counsellors in British Columbia
Canadian Counselling and Psychotherapy Association	Canadian Certified Counsellors across provinces
Inclusive Therapists	Filters for gender identity, neurodivergence-affirming practice and sliding scale
Pink Therapy	International directory of therapists trained in gender, sex and relationship diversity
Queer Menopause	Queer, trans, non-binary and intersex experiences of menopause
ACON TransHub: Menopause and oestrogen cessation	Plain-language guide covering both physiological stories
Postpartum Support International	Perinatal peer and professional support

Crisis lines. If you're in immediate danger, call 911 (Canada and the US) or your local emergency number. In Canada, 988 is usually the best first call for a mental health crisis without immediate danger.

Region	Line	How
Canada	9-8-8 Suicide Crisis Helpline	Call or text 988, 24/7, English and French
Canada	Trans Lifeline	1-877-330-6366, peer support by and for trans people
Canada	Hope for Wellness	1-855-242-3310, Indigenous-led, 24/7
Canada	Kids Help Phone	1-800-668-6868 or text CONNECT to 686868, 24/7
US	988 Suicide & Crisis Lifeline	Call or text 988, 24/7
US	Trans Lifeline	1-877-565-8860
US	The Trevor Project	1-866-488-7386 or text START to 678678 (LGBTQ+ under 25)
UK	Samaritans	116 123, 24/7
Australia	Lifeline	13 11 14, 24/7
Elsewhere	Find A Helpline	Search by country

Sources

Badawy Y, et al. The risk of depression in the menopausal stages: a systematic review and meta-analysis. J Affect Disord. 2024.
Bloch M, Schmidt PJ, Danaceau M, Murphy J, Nieman L, Rubinow DR. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry. 2000;157(6):924–930. doi:10.1176/appi.ajp.157.6.924
Brinton RD, et al. Perimenopause as a neurological transition state. Nat Rev Endocrinol. 2015;11(7):393–405.
Cohen LS, et al. Risk for new onset of depression during the menopausal transition: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry. 2006;63(4):385–390.
Evans J, Heron J, Francomb H, Oke S, Golding J. Cohort study of depressed mood during pregnancy and after childbirth. BMJ. 2001;323:257. doi:10.1136/bmj.323.7307.257
Georgakis MK, et al. Association of age at menopause and duration of reproductive period with depression after menopause. JAMA Psychiatry. 2016;73(2):139–149.
Gordon JL, et al. Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: a randomized clinical trial. JAMA Psychiatry. 2018;75(2):149–157.
Gordon JL, et al. Suicidality should be considered for inclusion in the diagnostic criteria for PMDD. Lancet Psychiatry. 2024.
Hickey M, et al. What happens after menopause? (WHAM): impact of risk-reducing salpingo-oophorectomy on depressive and anxiety symptoms at 24 months. Gynecol Oncol. 2024. doi:10.1016/j.ygyno.2024.10.031
Kelley CE, Ariel D. A review of menopause in transgender and gender diverse individuals. Curr Opin Obstet Gynecol. 2025. doi:10.1097/GCO.0000000000001013
Li Y, et al. Efficacy and safety of menopausal hormone therapy for depressive symptoms in perimenopausal women: a systematic review and meta-analysis. J Affect Disord. 2026. doi:10.1016/j.jad.2026.121892
Rocca WA, et al. Long-term risk of depressive and anxiety symptoms after early bilateral oophorectomy. Menopause. 2018;25(11):1275–1285.
Schmidt PJ, et al. Effects of estradiol withdrawal on mood in women with past perimenopausal depression: a randomized clinical trial. JAMA Psychiatry. 2015;72(7):714–726.
Soares CN, et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001;58(6):529–534.
Wikman A, et al. Prevalence and correlates of current suicidal ideation in women with premenstrual dysphoric disorder. BMC Women's Health. 2022;22:35.
Yan H, et al. Premenstrual disorders and suicidal ideation, plan and attempt: a systematic review and meta-analysis. J Affect Disord. 2021.
Doyle DM, Lewis TOG, Barreto M. A systematic review of psychosocial functioning changes after gender-affirming hormone therapy among transgender people. Nat Hum Behav. 2023.
Baker KE, et al. Hormone therapy, mental health, and quality of life among transgender people: a systematic review. J Endocr Soc. 2021;5(4):bvab011.
Moseley RL, Druce T, Turner-Cobb JM. "When my autism broke": a qualitative study spotlighting autistic voices on menopause. Autism. 2020;24(6):1423–1437.
Green R, Santoro N. Menopausal symptoms and ethnicity: the Study of Women's Health Across the Nation. Womens Health (Lond). 2009;5(2):127–133.
MGH Center for Women's Mental Health: perimenopausal depression risk; PMDD and suicidality. womensmentalhealth.org
SWAN (Study of Women's Health Across the Nation): depression and menopause. swanstudy.org
NICE guideline NG23: Menopause: identification and management (updated 2024). nice.org.uk/guidance/ng23
Boyd C, Wrigley M, et al. ADHD and the female reproductive stages: menstruation, perinatal and menopause. Arch Womens Ment Health. 2026;29:89. doi:10.1007/s00737-026-01718-x
Kooij JJS, de Jong M, et al. Research advances and future directions in female ADHD. Front Glob Womens Health. 2025. PMID 40692967
Westwood S. LGBTQ+ menopause: literature review, knowledge gaps and research agenda. Health. 2025 (online 2024). doi:10.1177/13634593241270923
Harlow SD, et al. Disparities in reproductive aging and midlife health between Black and White women: SWAN. Women's Midlife Health. 2022;8:3.
Hendriks O, et al. Menopausal suicidality and fragmented care: a qualitative study of carer and clinician perspectives. Health Expectations. 2026;29(4). Funded by Newson Health Research & Education.

All five studies originally drawn from Nila's own pages have now been checked against the original papers (Sept 25, 2026).

Piece 6 of 6 · Risk gathers around the change itself. · Framework: Human-centred evidence

When hormones shift, mental health shifts with them